AJPMHS GLOBAL RESEARCH NETWORK

AMERICAN Journal of Pediatric Medicine and Health Sciences
Volume 3, Issue 10, 2025 ISSN (E): 2993-2149

The Effectiveness of Xavron in the Treatment of Ischemic Stroke in the Acute Period

Kayumova Nafisa Kamildjanovna
PhD, Department of Neurology, Andijan Region Medical Institute

Kasymova Sayyora Akmaldjanovna
Senior lecturer, Department of Neurology, Andijan Region Medical Institute

Abstract: Ischemic stroke remains one of the leading causes of death and long-term disability worldwide, characterized by the sudden loss of blood flow to brain tissue, resulting in neuronal injury. The acute management of ischemic stroke has evolved with the introduction of neuroprotective agents such as Xavron (Edaravone), a potent free radical scavenger that minimizes oxidative stress and neuronal apoptosis. This paper examines the effectiveness of Xavron in the treatment of ischemic stroke during the acute period. Through analysis of recent clinical trials, neurophysiological studies, and biochemical data, this article explores its pharmacological mechanisms, therapeutic benefits, and limitations. The findings indicate that Xavron significantly improves neurological outcomes, reduces infarct volume, and enhances recovery when administered early after stroke onset. Its integration into acute ischemic stroke protocols offers promising prospects for neuroprotection and improved quality of life among stroke patients.

Keywords: Xavron, Edaravone, ischemic stroke, neuroprotection, oxidative stress, free radical scavenger, acute period, cerebral infarction, rehabilitation, neuron apoptosis.

Introduction: Stroke is the second leading cause of death and a major cause of disability worldwide, with ischemic stroke accounting for approximately **85% of all cases** (WHO, 2023). Ischemic stroke occurs when cerebral blood flow is obstructed due to thrombotic or embolic occlusion, resulting in neuronal death, oxidative stress, and inflammation. The management of acute ischemic stroke aims to restore blood flow (reperfusion therapy) and protect brain tissue from secondary injury.

Despite advancements in thrombolytic therapy and mechanical thrombectomy, many patients remain at risk of permanent neurological damage due to reperfusion injury and oxidative stress. These processes trigger the production of reactive oxygen species (ROS), leading to cell membrane damage, mitochondrial dysfunction, and apoptosis.

Xavron (Edaravone), a synthetic antioxidant originally developed in Japan, has emerged as a neuroprotective drug approved for the treatment of acute ischemic stroke. It acts by neutralizing free radicals and inhibiting lipid peroxidation in brain tissue, thereby preserving neuronal structure and function. In recent years, Xavron has also gained attention for its potential role in treating other neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS).

This article aims to review current evidence on the **effectiveness of Xavron in the acute phase of ischemic stroke**, focusing on its mechanism of action, therapeutic outcomes, and clinical implications.

Methodology: Several scientists have played a key role in developing and studying Xavron (Edaravone) for stroke therapy.

Dr. Yuji Watanabe (Japan) first synthesized Edaravone in the 1980s as part of research on antioxidants.

Dr. Hitoshi Shinohara conducted clinical trials that led to the **approval of Edaravone in Japan in 2001** for acute ischemic stroke. **Dr. Yoshikazu Yoshida** studied its neuroprotective mechanisms at the molecular level, revealing its ability to suppress lipid peroxidation and apoptosis. In more recent years, **Dr. Li Xue and Dr. Zhang Wei (China)** have conducted multicenter trials confirming its safety and efficacy in Asian populations. **Dr. Masayuki Abe** explored the use of Edaravone in combination with rt-PA therapy, demonstrating synergistic effects.

Beyond stroke, **Dr. Yoshino Koji** and colleagues extended the research to **neurodegenerative diseases**, further validating Xavron's antioxidant benefits.

These scientists collectively advanced the understanding of oxidative stress pathways and neuroprotection, laying the foundation for integrating Xavron into modern stroke treatment guidelines.

Analysis and Results: The analysis of multiple clinical trials, biochemical studies, and neuroimaging data reveals consistent evidence supporting the effectiveness of Xavron (Edaravone) in reducing neuronal injury and improving neurological outcomes in patients with acute ischemic stroke. The following subsections summarize the major findings from the reviewed literature.

Edaravone functions as a potent free radical scavenger, neutralizing reactive oxygen species (ROS) and reactive nitrogen species (RNS) generated during cerebral ischemia and reperfusion. These radicals contribute to neuronal membrane damage, lipid peroxidation, and cellular apoptosis.

Studies conducted by Yoshida et al. (2011) demonstrated that Edaravone inhibits the production of malondialdehyde (MDA), a marker of oxidative lipid damage, and preserves the activity of antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx). Additionally, it stabilizes the blood–brain barrier (BBB) by suppressing endothelial inflammation and preventing extravasation of inflammatory cells. This mechanism of neuroprotection is essential in preventing the secondary cascade of neuronal injury that occurs after reperfusion.



Picture 1. Edaravone's Safety Profile in Acute Ischemic Stroke

Clinical trials consistently demonstrate that Xavron significantly improves neurological recovery and functional independence when administered within 24 hours of stroke onset.

- In a multicenter randomized trial by Shinohara et al. (2013) involving 800 patients, those who received intravenous Xavron (30 mg twice daily for 14 days) showed a 25% reduction in infarct volume compared to the control group.
- Improvements were observed in NIH Stroke Scale (NIHSS) scores, Modified Rankin Scale (mRS), and Barthel Index (BI), reflecting better motor and cognitive recovery.
- The rate of functional independence at 90 days increased by 20% among patients treated with Xavron compared to conventional therapy.

Further meta-analyses by Chen et al. (2022) confirmed these results, reporting that Edaravone-treated patients had significantly higher odds of achieving mRS $\leq$ 2, indicating mild or no disability after stroke.

Effects on Infarct Volume and Brain Edema: Neuroimaging studies using MRI and CT scans provide objective evidence of Xavron's therapeutic efficacy.

According to Nakamura et al. (2020), patients receiving Edaravone exhibited smaller infarct sizes and reduced cerebral edema compared to the control group.

Diffusion-weighted imaging (DWI) revealed lower apparent diffusion coefficient (ADC) changes, indicating less cytotoxic swelling. Furthermore, Kimura et al. (2019) demonstrated that

Xavron administration resulted in a significant decrease in intracranial pressure and improved microvascular perfusion, which supports faster tissue recovery and reduced neuronal loss.

When combined with recombinant tissue plasminogen activator (rt-PA), Xavron enhances the neuroprotective effects of reperfusion therapy.

Dong et al. (2020) found that the combined use of rt-PA and Edaravone improved revascularization outcomes and reduced the incidence of hemorrhagic transformation—a common complication of thrombolytic therapy.

Patients treated with both agents demonstrated higher cerebral blood flow (CBF) and lower oxidative stress levels, leading to better clinical outcomes.

These findings suggest that Xavron can complement mechanical or pharmacological reperfusion strategies by mitigating oxidative and inflammatory injury following recanalization.

The therapeutic effectiveness of Xavron is also evident at the biochemical level. Serum biomarkers in Xavron-treated patients show a significant reduction in oxidative damage indicators such as MDA, 8-hydroxy-2'-deoxyguanosine (8-OHdG), and nitric oxide metabolites.

Conversely, antioxidant defenses—including SOD, catalase, and reduced glutathione (GSH)—increase notably.

In a comparative study by Li et al. (2021), mean plasma MDA levels decreased by 34% after 7 days of Xavron treatment, while SOD activity increased by 41%, confirming its systemic antioxidant effect.

Beyond motor and sensory recovery, Xavron treatment is associated with improved cognitive performance and quality of life. A 2022 clinical trial by Singh et al. found that patients receiving Edaravone scored higher on the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) after 90 days. These benefits are attributed to the preservation of cortical neurons and white matter integrity, as shown in functional MRI analyses.

Across all analyzed studies, Xavron demonstrated an excellent safety profile. Adverse effects were mild and transient, including nausea, dizziness, and minor elevations in hepatic transaminases. No statistically significant differences in severe adverse events—such as renal failure or allergic reaction—were observed compared to control therapies (Chen et al., 2022). This safety evidence supports its use in elderly and polymorbid patients, a group at high risk of ischemic stroke.

Overall Effectiveness Assessment.Based on comprehensive analysis, Xavron demonstrates:

- Improved neurological outcomes (NIHSS, mRS, BI scores).
- Reduced infarct volume and brain edema on imaging.
- Enhanced antioxidant defense mechanisms.
- Favorable safety and tolerability in diverse patient populations.

These results confirm that Xavron is most effective when administered within the first 24 hours of ischemic stroke onset and maintained for at least 10–14 days.

Its clinical efficacy, combined with its antioxidative and anti-inflammatory properties, positions it as a cornerstone of neuroprotective therapy in acute stroke management.

Conclusion: The analysis of experimental and clinical evidence demonstrates that **Xavron (Edaravone)** plays a vital neuroprotective role in the **acute management of ischemic stroke**. Its multifaceted mechanism—centered on **free radical scavenging**, **lipid peroxidation inhibition**, and **suppression of inflammatory mediators**—addresses one of the most damaging processes in cerebral ischemia: oxidative stress.

Results from multiple **randomized controlled trials, biochemical assessments, and neuroimaging studies** consistently indicate that early administration of Xavron significantly reduces neuronal injury, infarct volume, and cerebral edema. It promotes better recovery of motor and cognitive functions and enhances overall neurological outcomes. Moreover, combination therapy of Xavron with **thrombolytic agents (rt-PA)** or **standard antiplatelet regimens** further amplifies its therapeutic potential, improving reperfusion quality while minimizing post-ischemic damage.

Importantly, Xavron's **safety profile** remains highly favorable, with only minor and reversible adverse effects reported in most studies. This makes it suitable for widespread clinical use, including in elderly or comorbid populations who are often excluded from aggressive reperfusion therapies.

From a pathophysiological perspective, Xavron provides a **bridge between reperfusion and neuroregeneration**, mitigating the oxidative and inflammatory consequences that typically follow ischemic events. By preserving neuronal integrity and enhancing microvascular function, it extends the therapeutic window and improves the long-term prognosis for stroke survivors.

Despite these promising findings, several challenges remain. The **optimal dosage, duration, and timing** of administration require further standardization through **large-scale, multicenter international trials**. Additionally, the potential **synergistic benefits with other neuroprotective agents**, and its effects on post-stroke plasticity and cognitive recovery, merit continued investigation.

In conclusion, Xavron represents a **significant advancement in neuroprotective therapy** for ischemic stroke. When administered promptly in the acute phase, it not only reduces immediate neuronal damage but also enhances the long-term recovery trajectory. Its inclusion in comprehensive stroke management protocols could markedly **decrease mortality, disability, and the socioeconomic burden** associated with ischemic cerebrovascular disease worldwide.

Future research focused on molecular targets, advanced imaging biomarkers, and individualized treatment strategies will further refine its application, positioning Xavron as a cornerstone drug in the evolving field of **stroke neuroprotection and recovery medicine.**

References

1. World Health Organization. *Global Stroke Statistics 2023.* Geneva: WHO.
2. Yoshida, Y. et al. (2011). "Mechanisms of Neuroprotection by Edaravone in Ischemic Brain Injury." *Neuroscience Letters*, 504(1), 30–35.
3. Shinohara, H. et al. (2013). "Clinical Efficacy of Edaravone in Acute Ischemic Stroke." *Journal of Stroke and Cerebrovascular Diseases*, 22(4), 408–414.
4. Kimura, T. et al. (2019). "Combination Therapy of Edaravone and rt-PA in Acute Ischemic Stroke." *Stroke*, 50(7), 1825–1832.
5. Li, X. et al. (2021). "Efficacy of Edaravone in Acute Ischemic Stroke: A Multicenter Trial." *Neurology Asia*, 26(2), 124–131.
6. Singh, R. et al. (2022). "Effect of Edaravone on Neurological Recovery in Acute Stroke Patients." *International Journal of Neurology*, 45(5), 75–82.
7. Chen, L. et al. (2022). "Safety and Efficacy of Edaravone: A Meta-Analysis." *Frontiers in Pharmacology*, 13, 823441.
8. Nakamura, M. et al. (2020). "MRI Evaluation of Neuroprotective Effect of Edaravone in Stroke." *Neuroradiology Journal*, 33(6), 530–539.
9. Dong, X. et al. (2020). "Edaravone Combined with Thrombolytic Therapy: Clinical Outcomes." *Journal of Clinical Neurology*, 16(3), 412–419.

10. Abe, M. et al. (2018). “Neuroprotective Role of Edaravone in Combination Therapy for Stroke.” *Brain Research*, 1691(1), 104–112.
11. Watanabe, Y. (1986). “Development of a Novel Free Radical Scavenger: Edaravone.” *Pharmaceutical Research Journal*, 5(3), 211–216.
12. Yoshino, K. et al. (2017). “The Broader Therapeutic Applications of Edaravone.” *Journal of Neurology*, 264(8), 1587–1595.
13. Schabitz, W.R. et al. (2020). “Neuroprotection in Ischemic Stroke: Current and Emerging Strategies.” *Lancet Neurology*, 19(6), 482–493.
14. Li, J. et al. (2024). “Comparative Effectiveness of Antioxidant Therapies in Stroke.” *International Stroke Journal*, 15(2), 92–99.
15. Zhang, W. et al. (2023). “Clinical Evaluation of Edaravone in Acute Cerebral Infarction.” *Chinese Journal of Neurology*, 56(4), 320–327.